ABT : Summary for Abbott Laboratories Common Stoc - Yahoo Finance

U.S. Markets open in 9 hrs 12 mins

Abbott Laboratories (ABT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
40.90-0.03 (-0.07%)
At close: 4:01PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close40.93
Bid0.00 x
Ask0.00 x
Day's Range40.53 - 41.04
52 Week Range36.00 - 45.79
Avg. Volume9,149,924
Market Cap70.39B
PE Ratio (TTM)27.00
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire16 hours ago

    New Data Confirms Abbott's Dorsal Root Ganglion Stimulation Offers Greater Treatment Success over Traditional Spinal Cord Stimulation

    ABBOTT PARK, Ill., Jan. 17, 2017 /PRNewswire/ -- New data published in the January edition of Pain has confirmed the superiority of Abbott's dorsal root ganglion (DRG) stimulation therapy over traditional spinal cord stimulation (SCS) for patients suffering from complex regional pain syndrome (CRPS). The data, which include both short-term and long-term data from the ACCURATE study, also suggested that DRG stimulation benefits patients' total mood and activity levels. Abbott is the only company in the world approved to offer DRG stimulation.

  • Barrons.com4 days ago

    [$$] Credit Suisse Likes Expedia's Mash-Up of Brands

    Abbott Laboratories • ABT-NYSE Overweight • Price $40.74 on Jan. 9 by Barclays With the Jan. 4 close of Abbott’s acquisition of medical-device maker St. Jude Medical (STJ), we are updating our model to include both that purchase and recent divestitures (including Abbott medical optics and vascular units). For 2018, our EPS estimate has increased three cents, to $2.80, to reflect approximately 10% organic EPS growth and additional accretion from St. Jude of some 10 cents in earnings. In our view, Abbott shares have been dislocated by the noise around these deals and near deals, and we see this as a unique opportunity to buy a quality asset at a discount.

  • PR Newswire5 days ago

    Abbott Announces U.S. Launch and First Commercial Use of the New EnSite™ Precision Cardiac Mapping System

    ABBOTT PARK, Ill., Jan. 12, 2017 /PRNewswire/ -- Abbott (ABT) announced today the U.S. launch and the first commercial uses of the new EnSite Precision™ cardiac mapping system and Advisor™ FL Circular Mapping Catheter, Sensor Enabled™ to map cardiac arrhythmias during ablation treatments. Since the landmark clinical cases by Dr. Day, additional procedures supported by the new EnSite Precision cardiac mapping system have occurred in 12 states nationwide, supporting ablation procedures to treat complex arrhythmias. Abbott expects its new cardiac mapping technology to quickly become a new standard for use in treating patients experiencing arrhythmias from multiple origins in the heart.